Published • loading... • Updated
Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement
The financing will fund AI-driven drug discovery programs, with insiders subscribing for 2.12 million units and the company paying $26,810 in finder’s fees.
- On Monday, August 31, 2026, Vancouver-based Rakovina Therapeutics Inc. closed the second and final tranche of its upsized private placement, issuing 5,970,000 units at $0.10 per unit for gross proceeds of $597,000.
- Total gross proceeds reached $1,991,000 after Rakovina increased the maximum offering from $1,500,000 following the first tranche closing on August 12, 2026, for $1,394,000.
- Insiders subscribed for 2,120,000 units generating $212,000 across the offering, while Rakovina paid $26,810 in cash finder's fees and issued 264,100 finder's units to arm's length finders.
- Proceeds will support advancement of the kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through Variational AI collaboration, according to Chief Executive Officer Kim Oishi of Rakovia Therapeutics.
- Following the August 19, 2026, Annual Meeting, the company appointed Dr. Petra Hamerlik to its Board, while Jeffrey Bacha retired as a director to continue in an advisory capacity.
Insights by Ground AI
9 Articles
9 Articles
Cambridge Times+6 Reposted by 6 other sources
Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement
VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the second and final tranche…
·Cambridge, Canada
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left6Leaning Right2Center1Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
11%
R 22%
Factuality
To view factuality data please Upgrade to Premium
